• Join
  • Login
  • Contact

Search abstracts

Pharmacokinetic characterization of krca-0008 as a novel potent and selective anaplastic lymphoma kinase inhibitor for anticancer treatment

  • In: Poster presentation
  • At: Seoul (South Korea) (2017)
  • Type: Poster
  • Poster code: POS-PAA-001
  • By: AHN, Sung-Hoon (Kangwon National University, College of Pharmacy, Chuncheon, Korea, Republic Of)
  • Co-author(s): Sung-Hoon Ahn: College of Pharmacy, Kangwon National University, Chuncheon, Korea, Republic Of
  • Abstract:


    KRCA-0008, bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines, has been under development as a potent and selective Anaplastic lymphoma kinase (ALK) and Ack1 dual inhibitor for anti-cancer treatment. KRCA-0008 has in vivo efficacy with a modest tumor growth inhibition in xenograft mice model bearing H3122 human lung..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses